Bevacizumab

Bevacizumab is a laboratory-made antibody (a targeted drug) that blocks a protein called VEGF, which tumors use to grow new blood vessels. By cutting off this blood supply, the drug helps slow tumor growth. It is given by intravenous infusion, usually in combination with chemotherapy. It is sold under brand names including Avastin and several approved biosimilars.

Origin

Developed by Genentech and first approved by the FDA in 2004 for metastatic colorectal cancer, bevacizumab was the first anti-angiogenic cancer drug to reach the market. Its name follows the WHO antibody naming system: the "-zu-" segment indicates a humanized antibody and "-mab" identifies it as a monoclonal antibody.

Significance in Asbestos Context

For pleural mesothelioma patients, bevacizumab is most relevant as part of the MAPS regimen (cisplatin, pemetrexed, and bevacizumab) which the French MAPS trial (2016) showed extended median overall survival by about 2.7 months compared with chemotherapy alone. It became a recognized first-line option in many treatment guidelines for eligible patients before immunotherapy (nivolumab plus ipilimumab) emerged as another front-line choice. Not every patient qualifies: people with uncontrolled high blood pressure, recent bleeding, major surgery within the past month, or significant cardiovascular disease are usually excluded. Whether you received, were offered, or were denied bevacizumab can appear in your medical records and may matter to documenting the treatment course in your claim.

Example Sentence

"After her pleural mesothelioma diagnosis, her oncologist discussed adding bevacizumab to the standard cisplatin and pemetrexed chemotherapy, based on the survival benefit shown in the MAPS trial."

Related Terms

Pemetrexed, Cisplatin, Angiogenesis, Malignant Pleural Mesothelioma, MAPS Trial, Monoclonal Antibody

Notes

• Ask your oncologist whether you are a candidate for bevacizumab-containing chemotherapy, and if not, why. Common disqualifiers include uncontrolled hypertension, recent bleeding, blood clots, or planned surgery.
• Have your blood pressure checked before every infusion; report nosebleeds, blood in urine or stool, severe headaches, or new shortness of breath promptly, as these can signal serious side effects.
• Tell every treating physician you are on bevacizumab before any procedure or surgery; the drug must typically be stopped at least 28 days before and after surgery to allow wound healing.
• Keep copies of all infusion records, lab results, and imaging reports. Treatment history is often relevant to both medical care continuity and asbestos claim documentation.
• Ask about biosimilars (such as Mvasi or Zirabev), which are FDA-approved equivalents and may affect cost or insurance coverage.